Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Regulations vary and are subject to change
Oral GLP-1s and New Formulations: The December 2025 approval of oral semaglutide (Wegovy pill) and the anticipated approval of orforglipron (Eli Lilly's non-peptide oral GLP-1) in 2026 will expand the patient pool significantly
We will continue to monitor the phenomenal up-take of GLP-1 drugs (recognizing its growing pipeline shown in the chart above) and patients perspectives of the use of these medications both those people prescribed them to treat medical obesity and those consumers willing to pay for them out-of-pocket
Dumzil (1970), p
No, anxiety is not listed as a recognized adverse effect in the FDA-approved prescribing information for Mounjaro or Zepbound, and major clinical trials did not identify anxiety as a common adverse event
Chem Commun (Camb) 48 , 58355837, (2012)
